FMP

FMP

Enter

IDYA - IDEAYA Biosciences, ...

photo-url-https://images.financialmodelingprep.com/symbol/IDYA.png

IDEAYA Biosciences, Inc.

IDYA

NASDAQ

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

23.14 USD

-0.01 (-0.04322%)

Operating Data

Year

2019

2020

2021

2022

2023

2024

2025

2026

2027

2028

Revenue

4.34B

4.17B

4.62B

5.62B

5.66B

6.08B

6.52B

7B

7.51B

8.07B

Revenue %

-

-3.81

10.69

21.81

0.66

7.34

7.34

7.34

7.34

Ebitda

1.73B

1.38B

2.16B

2.17B

2.11B

2.38B

2.55B

2.74B

2.94B

3.15B

Ebitda %

39.92

32.99

46.81

38.53

37.22

39.09

39.09

39.09

39.09

Ebit

631M

168M

1.05B

823M

769M

844.33M

906.29M

972.81M

1.04B

1.12B

Ebit %

14.55

4.03

22.68

14.63

13.58

13.9

13.9

13.9

13.9

Depreciation

1.1B

1.21B

1.11B

1.34B

1.34B

1.53B

1.64B

1.76B

1.89B

2.03B

Depreciation %

25.37

28.96

24.13

23.9

23.64

25.2

25.2

25.2

25.2

Balance Sheet

Year

2019

2020

2021

2022

2023

2024

2025

2026

2027

2028

Total Cash

1.53B

1.03B

895M

1.04B

775M

1.36B

1.46B

1.56B

1.68B

1.8B

Total Cash %

35.4

24.81

19.38

18.47

13.69

22.35

22.35

22.35

22.35

Receivables

560M

684M

620M

699M

525M

783.2M

840.68M

902.38M

968.61M

1.04B

Receivables %

12.92

16.4

13.43

12.43

9.27

12.89

12.89

12.89

12.89

Inventories

32M

37M

63M

53M

45M

57.45M

61.66M

66.19M

71.04M

76.26M

Inventories %

0.74

0.89

1.36

0.94

0.79

0.95

0.95

0.95

0.95

Payable

289M

334M

347M

400M

390M

439.82M

472.09M

506.74M

543.93M

583.85M

Payable %

6.67

8.01

7.52

7.11

6.89

7.24

7.24

7.24

7.24

Cap Ex

-907M

-824M

-908M

-1.07B

-1.18B

-1.22B

-1.31B

-1.4B

-1.51B

-1.62B

Cap Ex %

-20.92

-19.76

-19.67

-19.06

-20.9

-20.06

-20.06

-20.06

-20.06

Weighted Average Cost Of Capital

Price

27.78

Beta

Diluted Shares Outstanding

171.4M

Costof Debt

9.19

Tax Rate

After Tax Cost Of Debt

-4.3

Risk Free Rate

Market Risk Premium

Cost Of Equity

Total Debt

7.74B

Total Equity

4.76B

Total Capital

12.5B

Debt Weighting

61.91

Equity Weighting

38.09

Wacc

6.54

Build Up Free Cash Flow

Year

2019

2020

2021

2022

2023

2024

2025

2026

2027

2028

Revenue

4.34B

4.17B

4.62B

5.62B

5.66B

6.08B

6.52B

7B

7.51B

8.07B

Ebitda

1.73B

1.38B

2.16B

2.17B

2.11B

2.38B

2.55B

2.74B

2.94B

3.15B

Ebit

631M

168M

1.05B

823M

769M

844.33M

906.29M

972.81M

1.04B

1.12B

Tax Rate

146.86

146.86

146.86

146.86

146.86

146.86

146.86

146.86

146.86

146.86

Ebiat

283.66M

231.23M

843.89M

55.33M

-360.33M

392.24M

421.02M

451.92M

485.09M

520.69M

Depreciation

1.1B

1.21B

1.11B

1.34B

1.34B

1.53B

1.64B

1.76B

1.89B

2.03B

Receivables

560M

684M

620M

699M

525M

783.2M

840.68M

902.38M

968.61M

1.04B

Inventories

32M

37M

63M

53M

45M

57.45M

61.66M

66.19M

71.04M

76.26M

Payable

289M

334M

347M

400M

390M

439.82M

472.09M

506.74M

543.93M

583.85M

Cap Ex

-907M

-824M

-908M

-1.07B

-1.18B

-1.22B

-1.31B

-1.4B

-1.51B

-1.62B

Ufcf

173.66M

531.23M

1.1B

311.33M

-33.33M

483.66M

726.78M

780.12M

837.37M

898.82M

Wacc

6.54

6.54

6.54

6.54

6.54

Pv Ufcf

453.97M

640.29M

645.09M

649.93M

654.8M

Sum Pv Ufcf

3.04B

Terminal Value

Growth In Perpetuity Method

Long Term Growth Rate

Wacc

6.54

Free Cash Flow T1

930.28M

Terminal Value

30.61B

Present Terminal Value

22.3B

Intrinsic Value

Enterprise Value

25.35B

Net Debt

6.96B

Equity Value

18.38B

Diluted Shares Outstanding

171.4M

Equity Value Per Share

107.26

Projected DCF

107.26 0.741%

DCF Levered

Download Excel

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep